EyePoint(EYPT)

12.88-0.84-6.12%

社区社区
资讯资讯
资料资料
公告公告

- 最新
- 推荐
- Eyepoint, Inc.盘中异动股价大跌5.15%
  市场透视 · 01-13
  Eyepoint, Inc.盘中异动股价大跌5.15%
- Eyepoint, Inc.盘中异动下午盘股价大跌5.04%报16.22美元
  市场透视 · 01-10
  Eyepoint, Inc.盘中异动下午盘股价大跌5.04%报16.22美元
- EyePoint获得独立数据安全监测委员会对Duravyu™在湿性年龄相关性黄斑变性关键三期临床试验的积极推荐
  美股速递 · 2025-11-19
  EyePoint获得独立数据安全监测委员会对Duravyu™在湿性年龄相关性黄斑变性关键三期临床试验的积极推荐
- EyePoint制药或与Cantor Fitzgerald联合提供及出售高达2亿美元的普通股
  美股速递 · 2025-11-07
  EyePoint制药或与Cantor Fitzgerald联合提供及出售高达2亿美元的普通股
- EyePoint 2025财年Q3业绩会总结及问答精华：DuraVu临床进展与市场前景
  业绩会速递 · 2025-11-06
  EyePoint 2025财年Q3业绩会总结及问答精华：DuraVu临床进展与市场前景
- EyePoint Pharmaceuticals Inc宣布启动Duravy治疗糖尿病性黄斑水肿的3期临床试验项目
  美股速递 · 2025-10-15
  EyePoint Pharmaceuticals Inc宣布启动Duravy治疗糖尿病性黄斑水肿的3期临床试验项目
- Eyepoint Pharmaceuticals, Inc.盘中异动股价大涨5.21%报13.94美元
  市场透视 · 2025-10-08
  Eyepoint Pharmaceuticals, Inc.盘中异动股价大涨5.21%报13.94美元
- Eyepoint Pharmaceuticals, Inc.盘中异动早盘急速拉升5.09%报12.49美元
  市场透视 · 2025-09-05
  Eyepoint Pharmaceuticals, Inc.盘中异动早盘急速拉升5.09%报12.49美元
- Eyepoint Pharmaceuticals, Inc.2024财年实现净利润-1.31亿美元，同比减少85.03%
  市场透视 · 2025-03-10
  Eyepoint Pharmaceuticals, Inc.2024财年实现净利润-1.31亿美元，同比减少85.03%
- Eyepoint Pharmaceuticals, Inc.盘中异动股价大跌5.02%报6.25美元
  市场透视 · 2025-03-06
  Eyepoint Pharmaceuticals, Inc.盘中异动股价大跌5.02%报6.25美元
- Eyepoint Pharmaceuticals, Inc.盘中异动早盘大幅上涨6.09%报6.45美元
  市场透视 · 2025-03-05
  Eyepoint Pharmaceuticals, Inc.盘中异动早盘大幅上涨6.09%报6.45美元
- Eyepoint Pharmaceuticals, Inc.盘中异动快速下跌5.10%报5.95美元
  市场透视 · 2025-03-04
  Eyepoint Pharmaceuticals, Inc.盘中异动快速下跌5.10%报5.95美元
- Eyepoint Pharmaceuticals, Inc.盘中异动临近午盘股价大涨5.08%报6.20美元
  市场透视 · 2025-02-28
  Eyepoint Pharmaceuticals, Inc.盘中异动临近午盘股价大涨5.08%报6.20美元
- Eyepoint Pharmaceuticals, Inc.盘中异动大幅上涨5.08%报6.83美元
  市场透视 · 2025-02-18
  Eyepoint Pharmaceuticals, Inc.盘中异动大幅上涨5.08%报6.83美元
- Eyepoint Pharmaceuticals, Inc.盘中异动早盘股价大涨5.23%
  市场透视 · 2025-02-14
  Eyepoint Pharmaceuticals, Inc.盘中异动早盘股价大涨5.23%
- Eyepoint Pharmaceuticals, Inc.盘中异动早盘快速下跌5.00%
  市场透视 · 2025-02-10
  Eyepoint Pharmaceuticals, Inc.盘中异动早盘快速下跌5.00%
- Eyepoint Pharmaceuticals, Inc.盘中异动股价大跌13.12%
  市场透视 · 2025-02-05
  Eyepoint Pharmaceuticals, Inc.盘中异动股价大跌13.12%
- Eyepoint Pharmaceuticals, Inc.盘中异动临近午盘快速上涨5.16%
  市场透视 · 2025-02-05
  Eyepoint Pharmaceuticals, Inc.盘中异动临近午盘快速上涨5.16%
- Eyepoint Pharmaceuticals, Inc.盘中异动股价大涨5.17%报8.13美元
  市场透视 · 2025-01-31
  Eyepoint Pharmaceuticals, Inc.盘中异动股价大涨5.17%报8.13美元
- Eyepoint Pharmaceuticals, Inc.盘中异动下午盘股价大跌5.16%报8.09美元
  市场透视 · 2025-01-28
  Eyepoint Pharmaceuticals, Inc.盘中异动下午盘股价大跌5.16%报8.09美元
公司概况
公司名称
EyePoint
所属市场
NASDAQ
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.eyepointpharma.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
EyePoint, Inc.于2008年3月19日在特拉华州注册成立，是一家临床阶段的生物制药公司，致力于开发和商业化创新疗法，以帮助改善患有严重视网膜疾病的患者的生活。公司采用其专有的生物可降解Durasert E技术进行持续的眼内药物输送，从而解决了频繁玻璃体内注射带来的难题。其主要候选产品DURAVYU是一种用于治疗血管内皮生长因子介导的视网膜疾病的在研疗法。
- 01-07
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 01-05
  关联方拟减持公告
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 2025-12-08
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-12-04
  关联方拟减持公告
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 2025-11-28
  关联方拟减持公告
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 2025-11-26
  关联方拟减持公告
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 2025-11-19
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-11-12
  关联方拟减持公告
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 2025-11-06
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-11-06
  季度报告
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2025-11-05
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-10-17
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-10-15
  [补充]招股说明书
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
- 2025-10-14
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-08-07
  员工持股计划
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans

分时
5日
日
周
月

数据加载中...

最高

13.94

今开

13.76

量比

0.73

最低

12.82

昨收

13.72

换手率

0.37%

EyePoint(EYPT)

公司概况

热议股票